|
1
|
Fulda S: Inhibitor of Apoptosis (IAP)
proteins in hematological malignancies: Molecular mechanisms and
therapeutic opportunities. Leukemia. 28:1414–1422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wheatley S and McNeish IA: Survivin: A
protein with dual roles in mitosis and apoptosis. Int Rev Cytol.
247:35–88. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soleimanpour E and Babaei E: Survivin as a
potential target for cancer therapy. Asian Pac J Cancer Prev.
16:6187–6191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanhueza C, Wehinger S, Bennett Castillo
J, Valenzuela M, Owen GI and Quest AF: The twisted survivin
connection to angiogenesis. Mol Cancer. 14:1982015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lladser A, Sanhueza C, Kiessling R and
Quest AF: Is survivin the potential Achilles' heel of cancer? Adv
Cancer Res. 111:1–37. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Altieri DC: Targeting survivin in cancer.
Cancer Lett. 332:225–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao J, Tenev T, Martins LM, Downward J
and Lemoine NR: The ubiquitin-proteasome pathway regulates survivin
degradation in a cell cycle-dependent manner. J Cell Sci.
113:4363–4371. 2000.PubMed/NCBI
|
|
11
|
Chen X, Duan N, Zhang C and Zhang W:
Survivin and tumorigenesis: Molecular mechanisms and therapeutic
strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tran J, Master Z, Yu JL, Rak J, Dumont DJ
and Kerbel RS: A role for survivin in chemoresistance of
endothelial cells mediated by VEGF. Proc Natl Acad Sci USA.
99:4349–4354. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Coumar MS, Tsai FY, Kanwar JR, Sarvagalla
S and Cheung CH: Treat cancers by targeting survivin: Just a dream
or future reality? Cancer Treat Rev. 39:802–811. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature.
391:806–811. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Chang S, Sun J, Zhu S, Pu C, Li
Y, Zhu Y, Wang Z and Xu RX: Targeted microbubbles for ultrasound
mediated short hairpin RNA plasmid transfection to inhibit survivin
gene expression and induce apoptosis of ovarian cancer A2780/DDP
cells. Mol Pharm. 12:3137–3145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scholz C and Wagner E: Therapeutic plasmid
DNA versus siRNA delivery: Common and different tasks for synthetic
carriers. J Control Release. 161:554–565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Paddison PJ, Caudy AA, Bernstein E, Hannon
GJ and Conklin DS: Short hairpin RNAs (shRNAs) induce
sequence-specific silencing in mammalian cells. Genes Dev.
16:948–958. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ling X and Li F: Silencing of
antiapoptotic survivin gene by multiple approaches of RNA
interference technology. Biotechniques. 36(450–454): 456–460.
2004.
|
|
20
|
Hannon GJ and Rossi JJ: Unlocking the
potential of the human genome with RNA interference. Nature.
431:371–378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mohr SE and Perrimon N: RNAi screening:
New approaches, understandings, and organisms. Wiley Interdiscip
Rev RNA. 3:145–158. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan Q, van der Laan LJ, Janssen HL and
Peppelenbosch MP: A dynamic perspective of RNAi library
development. Trends Biotechnol. 30:206–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu G and Luo J: A primer on using pooled
shRNA libraries for functional genomic screens. Acta Biochim
Biophys Sin (Shanghai). 44:103–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brummelkamp TR, Bernards R and Agami R: A
system for stable expression of short interfering RNAs in mammalian
cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li QX, Zhao J, Liu JY, Jia LT, Huang HY,
Xu YM, Zhang Y, Zhang R, Wang CJ, Yao LB, et al: Survivin stable
knockdown by siRNA inhibits tumor cell growth and angiogenesis in
breast and cervical cancers. Cancer Biol Ther. 5:860–866. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Igney FH and Krammer PH: Death and
anti-death: Tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Altieri DC: New wirings in the survivin
networks. Oncogene. 27:6276–6284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grossman D, McNiff JM, Li F and Altieri
DC: Expression and targeting of the apoptosis inhibitor, survivin,
in human melanoma. J Invest Dermatol. 113:1076–1081. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuan QZ, Wang CT, Mao YQ, Zhang P, Shi HS,
Li ZY, Pan L, Yu DD, Leng F, Chen X, et al: Enhanced tumor
radiosensitivity by a survivin dominant-negative mutant. Oncol Rep.
23:97–103. 2010.PubMed/NCBI
|
|
32
|
Pennati M, Binda M, Colella G, Folini M,
Citti L, Villa R, Daidone MG and Zaffaroni N: Radiosensitization of
human melanoma cells by ribozyme-mediated inhibition of survivin
expression. J Invest Dermatol. 120:648–654. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pennati M, Binda M, De Cesare M, Pratesi
G, Folini M, Citti L, Daidone MG, Zunino F and Zaffaroni N:
Ribozyme-mediated down-regulation of survivin expression sensitizes
human melanoma cells to topotecan in vitro and in vivo.
Carcinogenesis. 25:1129–1136. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang Z, Wang L, Wang H, Shang X, Niu W, Li
J and Wu Y: A novel mimovirus vaccine containing survivin epitope
with adjuvant IL-15 induces long-lasting cellular immunity and high
antitumor efficiency. Mol Immunol. 45:1674–1681. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang X, Chen Y, Ren J and Qu X: Small
interfering RNA for effective cancer therapies. Mini Rev Med Chem.
11:114–124. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Joo MK, Yhee JY, Kim SH and Kim K: The
potential and advances in RNAi therapy: Chemical and structural
modifications of siRNA molecules and use of biocompatible
nanocarriers. J Control Release. 193:113–121. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carvalho A, Carmena M, Sambade C, Earnshaw
WC and Wheatley SP: Survivin is required for stable checkpoint
activation in taxol-treated HeLa cells. J Cell Sci. 116:2987–2998.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo K, Song W, Gong Y, Hu S, Zhong W and
Qiu W: Down-Regulation of survivin expression by siRNA suppresses
proliferation and enhances chemosensitivity in human pancreatic
cancer cell line Panc-1. In: Proceedings of the 2015 Seventh
International Conference on Measuring Technology and Mechatronics
Automation. IEEE, Nanchang. 400–402. 2015.
|
|
39
|
Habib R, Akhtar J, Taqi M, Yu C and Zhang
C: Lentiviral vector-mediated survivin shRNA delivery in gastric
cancer cell lines significantly inhibits cell proliferation and
tumor growth. Oncol Rep. 34:859–867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng H, Tang C and Yin C: Oral delivery
of shRNA based on amino acid modified chitosan for improved
antitumor efficacy. Biomaterials. 70:126–137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Berget SM, Moore C and Sharp PA: Spliced
segments at the 5′terminus of adenovirus 2 late mRNA. Proc Natl
Acad Sci USA. 74:3171–3175. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chow LT, Gelinas RE, Broker TR and Roberts
RJ: An amazing sequence arrangement at the 5′ ends of adenovirus 2
messenger RNA. Cell. 12:1–8. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pan Q, Shai O, Lee LJ, Frey BJ and
Blencowe BJ: Deep surveying of alternative splicing complexity in
the human transcriptome by high-throughput sequencing. Nat Genet.
40:1413–1415. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chorev M and Carmel L: The function of
introns. Front Genet. 3:552012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lunghi M, Spano F, Magini A, Emiliani C,
Carruthers VB and Di Cristina M: Alternative splicing mechanisms
orchestrating post-transcriptional gene expression: Intron
retention and the intron-rich genome of apicomplexan parasites.
Curr Genet. 62:31–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Matzke MA, Primig M, Trnovsky J and Matzke
AJ: Reversible methylation and inactivation of marker genes in
sequentially transformed tobacco plants. EMBO J. 8:643–649.
1989.PubMed/NCBI
|
|
47
|
Zilberman D, Cao X and Jacobsen SE:
ARGONAUTE4 control of locus-specific siRNA accumulation and DNA and
histone methylation. Science. 299:716–719. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pal-Bhadra M, Bhadra U and Birchler JA:
RNAi related mechanisms affect both transcriptional and
posttranscriptional transgene silencing in Drosophila. Mol
Cell. 9:315–327. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dernburg AF, Zalevsky J, Colaiácovo MP and
Villeneuve AM: Transgene-mediated cosuppression in the C.
elegans germ line. Genes Dev. 14:1578–1583. 2000.PubMed/NCBI
|
|
50
|
Grishok A, Sinskey JL and Sharp PA:
Transcriptional silencing of a transgene by RNAi in the soma of
C. elegans. Genes Dev. 19:683–696. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lippman Z, May B, Yordan C, Singer T and
Martienssen R: Distinct mechanisms determine transposon inheritance
and methylation via small interfering RNA and histone modification.
PLoS Biol. 1:E672003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matzke MA and Birchler JA: RNAi-mediated
pathways in the nucleus. Nat Rev Genet. 6:24–35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Morris KV: RNA-mediated transcriptional
gene silencing in human cells. Curr Top Microbiol Immunol.
320:211–224. 2008.PubMed/NCBI
|
|
54
|
Morris KV, Chan SW, Jacobsen SE and Looney
DJ: Small interfering RNA-induced transcriptional gene silencing in
human cells. Science. 305:1289–1292. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J,
Lee J, Provost P, Radmark O, Kim S, et al: The nuclear RNase III
Drosha initiates microRNA processing. Nature. 425:415–419. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mendez C, Ahlenstiel CL and Kelleher AD:
Post-transcriptional gene silencing, transcriptional gene silencing
and human immunodeficiency virus. World J Virol. 4:219–244. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lund E, Güttinger S, Calado A, Dahlberg JE
and Kutay U: Nuclear export of microRNA precursors. Science.
303:95–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ohrt T, Merkle D, Birkenfeld K, Echeverri
CJ and Schwille P: In situ fluorescence analysis demonstrates
active siRNA exclusion from the nucleus by Exportin 5. Nucleic
Acids Res. 34:1369–1380. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gagnon KT and Corey DR: Argonaute and the
nuclear RNAs: New pathways for RNA-mediated control of gene
expression. Nucleic Acid Ther. 22:3–16. 2012.PubMed/NCBI
|
|
60
|
Ohrt T, Mutze J, Staroske W, Weinmann L,
Hock J, Crell K, Meister G and Schwille P: Fluorescence correlation
spectroscopy and fluorescence cross-correlation spectroscopy reveal
the cytoplasmic origination of loaded nuclear RISC in vivo in human
cells. Nucleic Acids Res. 36:6439–6449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Verdel A, Vavasseur A, Le Gorrec M and
Touat-Todeschini L: Common themes in siRNA-mediated epigenetic
silencing pathways. Int J Dev Biol. 53:245–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Castel SE and Martienssen RA: RNA
interference in the nucleus: Roles for small RNAs in transcription,
epigenetics and beyond. Nat Rev Genet. 14:100–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Burger K and Gullerova M: Swiss army
knives: Non-canonical functions of nuclear Drosha and Dicer. Nat
Rev Mol Cell Biol. 16:417–430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Allo M, Buggiano V, Fededa JP, Petrillo E,
Schor I, de la Mata M, Agirre E, Plass M, Eyras E, Elela SA, et al:
Control of alternative splicing through siRNA-mediated
transcriptional gene silencing. Nat Struct Mol Biol. 16:717–724.
2009. View Article : Google Scholar : PubMed/NCBI
|
